Illumina NovaSeq 6000 v1.5 Reagent Kit
Illumina has launched a new NovaSeq 6000 reagent kit that the company said could reduce sequencing costs for a human genome to $600.
The v1.5 kit offers improved quality, with an average Q30 score above 85 percent for read lengths up to 2x150 bp. Additional cycles per kit enables full support for unique molecular identifiers. The kits also double shelf life — up to six months — and are compatible with the new Illumina DNA PCR-Free Prep kit.
Adaptive Biotechnologies ImmunoSeq T-Map COVID Service
Adaptive Biotechnologies has launched the immunoSeq T-Map COVID, a proprietary research product and data-analysis service to measure the T cell immune response to vaccines in development and track the persistence of that response over time.
The product leverages data from more than 1,000 patients to provide researchers with a quantitative map of T cell receptors and SARS-CoV-2 antigens that elicit an immune response. These data will be available through Adaptive's cloud-based immunoSeq Analyzer and is powered by ImmuneCode, an open database developed in partnership with Microsoft.
Personalis NeXT Liquid Biopsy
Personalis has launched NeXT Liquid Biopsy, an exome-scale blood-based tumor-profiling assay for advanced-stage solid tumor cancer patients. According to the company, the test monitors over 20 times more genes than most targeted liquid biopsy panels on the market. Personalis believes its more comprehensive option can help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid in the development of next-generation cancer therapies.
For more new products and services, please visit the New Products page on our website.